Morgan Stanley Reiterates Buy Rating on Pharvaris N.V.
Morgan Stanley maintains its buy rating on Pharvaris N.V. with a $46 price target, a 32.53% upside from the current price.
Key Points
- Morgan Stanley reiterated its buy rating on Pharvaris N.V. (PHVS) with a price target of $46 on June 25, 2026.
- Morgan Stanley's $46 price target implies 32.53% upside from Pharvaris N.V.'s ($PHVS) current $34.71 share price.
- Shares of Pharvaris traded at $33.29 on Friday, with a market cap of about $2.33 billion and a forward P/E ratio indicating it's not yet profitable.
- Insiders at Pharvaris, including the CEO and Chief Medical Officer, have been active, with recent transactions reported in June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Morgan Stanley has reiterated its buy rating on Pharvaris N.V. (PHVS) with a price target of $46 as of June 25, 2026. The analyst behind this reaffirmation is Matthew Harrison. Shares of Pharvaris were trading at $33.29 on Friday.
Morgan Stanley vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Pharvaris N.V. Stock Down 1.7%
Shares of NasdaqGS:PHVS traded near $33.29 on Friday. Pharvaris N.V. has a market cap of approximately $2.33 billion. The company is not yet profitable, reflected in its negative forward P/E ratio of -12.65. The stock has a 52-week low of $16.72 and a high of $35.33. It has a 50-day moving average of $30.41 and a 200-day moving average of $26.65. Pharvaris also maintains a strong financial position with a current ratio of 11.24 and a quick ratio of 10.99.
$PHVS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Pharvaris N.V.
Insider activity at Pharvaris N.V. shows significant movement. On June 18, 2026, Chief Medical Officer Lu Peng sold 300 shares at an average price of $34.00 under a planned transaction. On the same day, Lu Peng also bought 300 shares at $2.59 in an unplanned move. Additionally, CEO Berndt Modig executed a planned sale of 2,291 shares at $31.07 on June 15, 2026.
Analysts Set New Price Targets
On June 25, 2026, Morgan Stanley maintained its buy rating on Pharvaris N.V. with a $46 price target. Other analysts have also shown optimism. Citizens maintained a buy rating with a $74 target on May 13, 2026, while Wolfe Research initiated coverage with a buy rating and a $42 target on April 9, 2026. The consensus among analysts is a strong buy, with an average target price of $46.09 based on 13 analyst opinions.
About Pharvaris N.V.
Pharvaris N.V. is a late-stage biopharmaceutical company headquartered in Zug, Switzerland. It focuses on developing and commercializing therapies for rare diseases, particularly those involving bradykinin-mediated angioedema. The company's lead product, deucrictibant, is in phase 3 trials for treating hereditary angioedema (HAE) and other related conditions. Pharvaris was founded in 2015 and is led by CEO Berndt Modig.
Bottom Line
Morgan Stanley's reaffirmation of its buy rating on Pharvaris N.V. highlights continued confidence in the company's potential. With shares trading at $33.29, the stock reflects a robust market interest, though it remains unprofitable. Insider transactions and analyst ratings provide valuable insights into the company's strategic direction and market perception.
Get Pharvaris N.V. alerts
New 13F filings, insider trades, and analyst moves on $PHVS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.